MicroRNA126 Is A Biomarker For Benign Infantile Hemangioma
Ayan Biswas, PhD1, William E. Shiels, DO2, Savita Khanna, PhD1, Richard Kirschner, MD2, Greg D. Pearson, MD2, Sashwati Roy, PhD1, Chandan K. Sen, PhD1, Gayle M. Gordillo, MD1.
1The Ohio State University, Columbus, OH, USA, 2Nationwide Childrens Hospital, Columbus, OH, USA.
Purpose: Infantile Hemangiomas (IH) have a unique pattern of rapid growth followed by a prolonged period of involution. Since 90% of IH spontaneously regress it is difficult to quantitatively assess the impact of treatment interventions on IH growth. The objective of this work was to identify a biomarker for IH growth to enable investigators to quantitatively assess the effectiveness of treatment interventions for IH.
Methods: A prospective longitudinal study was performed. All children were enrolled prior to 5 months of age. The diagnosis of IH was confirmed by Doppler ultrasound. Age matched healthy volunteers served as controls (n= 30 per group). Children with IH that received treatment for their tumors were excluded. Both groups were followed for 24 months with urine samples collected at 2,4,6, 9, 12, 18 and 24 months. Doppler ultrasound was done at those same time points to measure tumor size. MicroRNA126 (miR126) was measured in the urine samples of all children using quantitative real-time polymerase chain reaction (qPCR).
Results: The correlation between tumor size and urinary miR126 levels at 4 months of age had a correlation coefficient (r2) = 0.9867 and at 6 months of age r2 = 0.8139. In hemangioma subjects urinary miR126 levels were twice as high as age-matched controls at 4 months, 20 times higher at 6 months and similar to controls at 9 months. Conclusions: These are the first reported findings of a urinary biomarker that specifically correlate with patterns of IH growth.
Back to 2015 Annual Meeting Program